基于MKM的带电粒子放疗二次癌症风险模型:淋巴瘤与乳腺质子治疗应用
本研究提出一种显式考虑质子束辐射品质的二次癌症风险模型,将微剂量动力学模型(MKM)与Schneider超额绝对风险(EAR)模型结合,并应用于淋巴瘤和乳腺质子治疗患者队列。蒙特卡洛重算获得体素级辐射品质分布,结合流行病学参数化计算EAR。结果显示显式整合RBE对EAR估计有不可忽略的影响,且突变诱导的α/β值影响显著,α/β越低LET修正效应越大;但现代质子治疗总体二次癌症风险相比纯物理剂量估计并未显著增大。
要点
- 将MKM与Schneider模型结合,可显式考虑质子束辐射品质评估二次癌症风险。
- 显式整合RBE对EAR估计有不可忽略影响,α/β值越低LET修正效应越大。
- 现代质子治疗总体二次癌症风险相比纯物理剂量估计并未显著增大。
核心结论
- 考虑质子束特定辐射品质会影响EAR估计,提供更全面的二次癌症风险预测。
- 现代质子治疗总体二次癌症风险在多数 probable α/β值下相比纯物理剂量估计并未显著增大。
研究设计与样本
- 方法学研究,将MKM模型适配与Schneider模型结合计算EAR,并应用于淋巴瘤和乳腺质子治疗两个患者队列。
- 使用蒙特卡洛工具TOPAS重算质子治疗计划,获得体素级辐射品质分布。
- 结合流行病学参数化计算不同患者、器官及不同 tentative α/β值下的EAR。
主要发现
- 显式整合RBE对EAR估计的影响在所有评估病例中均不可忽略,相比未整合的plain Schneider方法。
- 突变诱导的α/β值对结果影响显著,较低的α/β比值与更大的LET修正效应相关。
临床怎么用
- 在质子治疗二次癌症风险评估中应显式考虑束流辐射品质(LET/RBE),而非仅用物理剂量。
- 组织特异性α/β值(尤其突变诱导相关)是风险建模的关键参数,需谨慎选择。
局限性
- 原文未报告模型验证、样本量、随访数据或临床结局。
- α/β值仅为 tentative 参数化,缺乏统一标准。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To introduce a new model formalism for the assessment of secondary cancer (SC) risk after proton therapy, accounting explicitly for the specific radiation quality of the beam, and to present results of a first application to two patient cohorts. METHODS: A dedicated adaptation of the microdosimetric kinetic model (MKM) model was combined with the Schneider model for excess absolute risk (EAR) calculation, extending its applicability from reference photon radiation to charged particles with different values of linear energy transfer. Plans for proton treatment of Lymphoma and Breast targets were recalculated with a Monte Carlo tool (TOPAS) to obtain voxel-by-voxel radiation quality distributions. To feed the model for computing an RBE for the specific endpoint of radiation-induced mutations, this information was joined with epidemiology-based parameterization to compute the EAR for the different patients, organs, and for different tentative α/β values of the involved tissues. RESULTS: A non-negligible impact of the explicit integration of RBE in the proposed model, as compared to estimates without (i.e. plain Schneider approach) is evident in all evaluated cases, with a strong impact of the α/β value for mutation induction. Lower levels of α/β ratio correlate with larger effects of the LET correction. CONCLUSIONS: Accounting for the specific radiation quality of proton beams impacts EAR estimation, providing a more comprehensive picture in terms of SC risk prediction. Our analysis confirmed, however, that overall SC risk associated with modern proton treatments is not dramatically larger than that achievable by pure physical dose-based estimates for the most probable α/β values.
引用
- Attili A, Algranati C, Cianchetti M, et al. A dedicated MKM-based radiobiological model for secondary cancer estimation in charged particle radiotherapy: An application in lymphomas and breast proton therapy. Radiother Oncol. 2025. PMID: 41429724. doi:10.1016/j.radonc.2025.111229
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。